Visceral adipose tissue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
It also ran Camp Hardy Combat Training Center in the Northern Training Area of Okinawa to train SF, Navy SEALs, and US Marines deploying to Vietnam. It also earned the Meritorious Unit Commendation for its work during the year 1973. Following the war in South Vietnam, and the withdrawal of American military forces from Southeast Asia, the emphasis on military actions shifted away from the Asia-Pacific region and focused more on Europe and NATO. Special Forces, which had grown to a total of seven groups in 1963, faced severe cuts in the peacetime army; as a result, 1st Group was inactivated 28 June 1974 at Ft. Bragg, NC. After a 10-year hiatus, the need for an Asian unconventional warfare force was recognized, and Alpha Company, 1st Battalion was reactivated at Fort Bragg on 15 March 1984. This company and the remainder of the 1st Battalion were assembled and deployed to Torii Station, Okinawa during the spring and summer of 1984. The 2nd and 3rd Battalions, along with Headquarters and Service Company were officially reactivated 4 September 1984 at Fort Lewis, Washington. Brought back to life as part of overall growth in the support to U.S. strategic efforts in Asia, the unit focused on the Pacific Command area of operations but were routinely deployed out of Asia to support unified commanders throughout the world. Unit members supported theater security engagement within the PACOM area of operations, contingency operations in Haiti, Central Asia, and Bosnia.
== Awards and honors == As an inventor and advocate for diversity in science and engineering, Bhatia has received numerous honors. She is the first female physician-scientist in history to be an elected member of all five national academies in the U.S.:
=== Medications === There are many drugs that can affect calcium level in the blood, and therefore PTH secretion. For example, many individuals may take a calcium carbonate supplement, which increases the calcium level in the blood. PTH is decreased. Many medications may also increase urination, furthering loss of calcium.
On 28 July, in his 90th year, our Honorary President Otto Hahn passed away. His name will be recorded in the history of humanity as the founder of the atomic age. In him Germany and the world have lost a scholar who was distinguished in equal measure by his integrity and personal humility. The Max Planck Society mourns its founder, who continued the tasks and traditions of the Kaiser Wilhelm Society after the war, and mourns also a good and much loved human being, who will live in the memories of all who had the chance to meet him. His work will continue. We remember him with deep gratitude and admiration. Fritz Strassmann wrote:
Sources: en.wikipedia.org
== Instrumentation == In DESI, there is a high-velocity pneumatically assisted electrospray jet that is continually directed towards the probe surface. The jet forms a micrometer-size thin solvent film on the sample where it can be desorbed. The sample can be dislodged by the incoming spray jet allowing for particles to come off in an ejection cone of analyte containing secondary ion droplets. A lot of study is still going into looking at the working principals of DESI but there are still some things known. The erosion diameter of the spray spot formed by DESI is known to be directly tied to the spatial resolution. Both the chemical composition and the texture of the surface will also affect the ionization process. The nebulizing gas used most commonly is N2 set at a typical pressure of 160 psi. The solvent is a combination of methanol and water, sometimes paired with 0.5% acetic acid and at a flow rate of 10 μL/min. The surface can be mounted it two different ways, one way consists of a surface holder that can carry 1 x 5 cm large disposable surface slides that lie on a stainless steel surface. The steel surface has a voltage applied to provide an appropriate surface potential. The surface potential that can be applied is the same at which the sprayer can be set at. The second surface is made with an aluminum block that has a built in heater, this allows for temperature control with temperatures up to 300 °C with newer stages having built in CCD's and light sources. Their spectra are that similar to ESI.
=== Optical isomerism === Glutamic acid is chiral; two mirror-image enantiomers exist: d(−), and l(+). The l form is more widely occurring in nature, but the d form occurs in some special contexts, such as the bacterial capsule and cell walls of bacteria (which produce it from the l form with the enzyme glutamate racemase) and can be found in small amounts in the liver and other organs of mammals, either directly from dietary sources or from production by the gut microbiota.
From the perspective of ground forces, apart from the occasional "oil rain" experienced by troops very close to spewing wells, one of the more commonly experienced effects of the oil field fires were the ensuing smoke plumes which rose into the atmosphere and then precipitated or fell out of the air via dry deposition and by rain. The pillar-like plumes frequently broadened and joined up with other smoke plumes at higher altitudes, producing a cloudy grey overcast effect, as only about 10% of all the fires corresponding with those that originated from "oil lakes" produced pure black soot filled plumes, 25% of the fires emitted white to grey plumes, while the remainder emitted plumes with colors between grey and black. For example, one Gulf War veteran stated:
Sources: en.wikipedia.org
Narrated by Sean Pertwee, directed by Mike Wallington, produced by George Haggerty, made by Kai Productions 28 December Incredible Evidence, an Equinox Special about the limits of DNA profiling; on the evidence of a fingerprint, with 16 points of similarity, known as ridge detail, 35 year old miner, Neville Lee of Mansfield Woodhouse, was arrested on 21 August 1991 for the rape of an 11 year old girl on Sunday 4 August 1991, at Clumber Park caravan site in Nottinghamshire; when the real rapist confessed at Worksop Magistrates Court, on 16 September 1991, Neville Lee had lost his £20,000 job, been beaten up when on 28 days remand in HM Prison Lincoln, and his house vandalised, with all the windows broken; he was hoping to be re-employed by British Coal at Bevercotes Colliery; 23 year old Kristopher Hermann John Pohnert was jailed for life at Nottingham Court on 30 April 1992 for stripping an 11 year old girl naked, whipping her, and raping her; Pohnert had been to boarding school in Devon and Buckland School in Lymington, Hampshire; he told police 'I have a thing about spanking young children'. Directed by Hilary Lawson, made by TVF
This loop is believed to play an important role in stabilizing the cyclotide structure through hydrogen bonding with residues from loops 3 and 5. Loops 2-6 also have highly conserved features, including the ubiquitous presence of just a single amino acid in loop 4 that is likely involved in sidechain-sidechain hydrogen bonding. Other conserved residues include a hydroxyl-containing residue in loop 3, a glycine residue in the final position of loop 3, a basic and a proline residue in the penultimate position in loop 5 of bracelet and Möbius cyclotides respectively, and an asparagine (or occasionally aspartic acid) residue at the putative cyclisation point in loop 6. It is of interest to note that not only are certain residues highly conserved, but the backbone and side chain angles are as well. With recent screening programs suggesting that the number of cyclotide sequences may soon reach the thousands, a database, CyBase, has been developed that offers the opportunity for comparisons of sequences and activity data for cyclotides. Several other families of circular proteins are known in bacteria, plants and animals and are also included in CyBase.
Schröder (1993, 2002) reviewed the issue of CPA dosage and recommended a dosage of 200 to 300 mg/day for CPA as a monotherapy and a dosage of 100 to 200 mg/day for CPA in combined androgen blockade (that is, CPA in combination with surgical or medical castration). However, the combination of CPA with castration for prostate cancer has been found to significantly decrease overall survival compared to castration alone. Hence, the use of CPA as the antiandrogen component in combined androgen blockade would appear not to be advisable. When used by intramuscular injection to treat prostate cancer, CPA is used at a dosage of 300 mg once a week. The combination of CPA with an estrogen such as ethinylestradiol sulfonate or low-dose diethylstilbestrol has been used as a form of combined androgen blockade and as an alternative to the combination of CPA with surgical or medical castration.
Dosages of bicalutamide of 10 mg, 30 mg, and 50 mg per day have been found to produce a "moderate" effect on sex hormone levels in men with prostate cancer (notably providing indication that the drug has clinically-relevant antiandrogen effects in males at a dosage as low as 10 mg/day). The elevated levels of gonadotropins and gonadal steroids associated with NSAA monotherapy is a unique endocrine state which can be described as "hypergonadotropic hypergonadism". Bicalutamide increases androgen and estrogen levels only in men, and does not do so in women. This is because androgen levels are comparatively far lower in women and in turn exert little to no basal suppression of the HPG axis. Minimal or no changes of importance in levels of total testosterone, free testosterone, dihydrotestosterone, estradiol, androstenedione (A4), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), 3α-androstanediol glucuronide (3α-ADG), progesterone, 17α-hydroxyprogesterone (17α-OHP), LH, FSH, prolactin, or SHBG have been observed in women with hirsutism with or without polycystic ovary syndrome that were treated with 25 or 50 mg/day bicalutamide for 6 to 12 months. However, in one study in women with polycystic ovary syndrome, 25 mg/day bicalutamide significantly decreased levels of total and free testosterone and significantly increased levels of SHBG.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.